A MULTICENTRE ASSESSMENT OF SUSTAINED RELEASE OXPRENOLOL IN THE TREATMENT OF HYPERTENSION IN OTD-PATIENT PRACTICE

Aim: Fifty-six patients with moderate essential hypertension (with diastolic blood pressure values between 106-120 mm Hg) showed inadequate control, problematic side effects, or a combination of both. Were selected for the study. Recently diagnosed patients and patients who discontinued treatment were also included in the study. Place and Duration: In the Lahore General Hospital Lahore for six months duration from July 2019 to December 2019. Methods: This study included 56 patients. The regimen consisted of 160mg of Oxprenolol in sustained release formulation (Trasicor l60 SR.) and 25mg of Chlorthalidone (Hygroton) administered once daily in the morning, for eight weeks. The mean duration of hypertension was five years, and the mean heart rate and blood pressure at the beginning of the study were 93- and 177/112-mm Hg, respectively. At the end of the study, mean heart rate and blood pressure were 77- and 145/89-mm Hg, respectively. 45 of 45 patients (80%) had diastolic hypotension of 95 mm Hg or less. Adverse reactions were observed in 10 patients (17.9%) and were mild; in no case was it necessary to discontinue treatment earlier due to adverse reactions. Conclusion: This study showed a combination of Oxprenolol slow release (Trasicor 160 SR.) and 25 mg chlortalidone (Hygroton) administered once daily cause normalization of blood pressure in about 80% of patients and a single morning dose of sustained release formulation in a patient in moderate essential hypertension improves compliance